Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported two sales of company common stock. On January 5, 2026, she sold 3,295 shares at $1.003 per share, and on January 6, 2026, she sold 5,512 shares at $1.012 per share. According to the disclosure, these sales were made under the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026.
After these transactions, Day directly holds 75,363 shares of AN2 Therapeutics common stock. Her equity awards also include 27,500 RSUs that vest in four annual installments starting January 1, 2024, and 46,500 RSUs that vest in four annual installments starting January 1, 2025, in each case subject to her continued service. The reported total reflects a prior purchase of 5,000 shares through the company’s employee stock purchase plan on September 30, 2025.
AN2 Therapeutics Chief Strategy Officer Stephen David Prior reported two small stock sales related to tax withholding on recently vested equity awards. On January 5, 2026, he sold 3,604 shares of common stock at $1.003 per share, and on January 6, 2026 he sold 2,858 shares at $1.012 per share. The filing explains that these sales were made under the terms of the grant to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. After the January 6 transaction, he beneficially owned 59,086 shares of common stock directly.
The filing also notes ongoing equity incentives: 10,125 RSUs vest over four years from November 4, 2024, 17,500 RSUs follow a schedule through January 1, 2026, and 28,000 RSUs vest over four years from January 1, 2025, in each case subject to continued service.
AN2 Therapeutics Chief Development Officer Sanjay Chanda reported two sales of AN2 Therapeutics common stock. On January 5, 2026, he sold 3,295 shares at $1.003 per share, and on January 6, 2026, he sold 5,956 shares at $1.012 per share. A footnote states these shares were sold under the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026, rather than as discretionary open‑market sales.
After these transactions, Chanda beneficially owned 75,823 shares of common stock directly. This amount includes 27,500 RSUs that vest annually in four equal parts from January 1, 2024, and 50,250 RSUs that vest annually in four equal parts from January 1, 2025, in each case subject to his continued service. The total also reflects a prior purchase of 5,000 shares under the company’s Employee Stock Purchase Plan on September 30, 2025.
AN2 Therapeutics officer reports small stock sales tied to RSU taxes. Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 17,923 shares of AN2 Therapeutics common stock on January 5, 2026 at a weighted average price of $1.0014 per share, followed by 6,931 shares on January 6, 2026 at $1.012 per share. According to the footnotes, these shares were sold pursuant to the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on January 1, 2026. After the reported transactions, Eizen directly beneficially owned 152,499 shares of common stock, which include multiple RSU awards that vest over several years, subject to his continued service.
AN2 Therapeutics (ANTX) filed its Q3 2025 10‑Q reporting lower losses and steady liquidity. For the quarter, operating expenses were $10.0 million, driven by $7.0 million in research and development and $3.0 million in general and administrative costs. Interest income of $0.7 million partially offset expenses, resulting in a net loss of $9.4 million, or $0.31 per share.
Cash, cash equivalents, and investments totaled $65.1 million, with management stating this is sufficient to fund its operating plan for at least 12 months from the financial statement issuance date. Year‑to‑date, operating cash outflows were $24.6 million, and the nine‑month net loss improved to $26.5 million from $43.8 million a year ago as expenses declined.
The company recorded reductions to research and development expense from non‑dilutive funding, including $3.5 million year‑to‑date from a NIAID contract and $1.5 million from a Gates Foundation grant. In June, 2,952,000 common shares were exchanged for pre‑funded warrants at a nominal exercise price. Shares outstanding were 27,402,024 as of November 3, 2025.
AN2 Therapeutics (ANTX) filed an 8-K to announce it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information under Item 2.02 is being furnished, not filed.
The company lists its principal executive offices at 1300 El Camino Real, Suite 100, Menlo Park, CA 94025, and provides a former address at 1800 El Camino Real, Suite D, Menlo Park, CA 94027.
AN2 Therapeutics (ANTX) insider activity: Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 2,819 shares of common stock at $1.14 on November 4, 2025, to satisfy tax withholding from RSU vesting. Following the transaction, he beneficially owns 177,353 shares.
The holdings figure includes RSU grants: 31,500 RSUs vesting annually in quarters from November 4, 2024; 22,500 RSUs vesting annually in thirds from January 1, 2025; and 45,000 RSUs with two-thirds vesting on January 1, 2026 and one-third on July 1, 2026, subject to continuous service. The total also reflects the purchase of 5,000 shares under the 2022 ESPP on September 30, 2025.
AN2 Therapeutics (ANTX) reported an insider transaction by Chief Strategy Officer Stephen David Prior. On 11/04/2025, he sold 765 shares of common stock at $1.14 per share, a sale made to satisfy tax withholding from the vesting of RSUs. Following this transaction, he beneficially owned 65,548 shares.
His equity includes 10,125 RSUs that vest 1/4 annually over four years from November 4, 2024, and 12,031 RSUs that vest on January 1, 2026, each contingent on continued service. The holdings also reflect the purchase of 5,000 shares under the 2022 Employee Stock Purchase Plan on September 30, 2025.
AN2 Therapeutics (ANTX) reported a director’s acquisition of 10,367 shares of common stock on 10/10/2025 via Form 4. The shares were issued in lieu of cash compensation under the company’s non‑employee director policy, and all shares vest immediately. The transaction was coded A and reported at a price of $0. Following this transaction, the director beneficially owned 63,749 shares, held directly.
AN2 Therapeutics (ANTX) reported an insider transaction on a Form 4. Director Kabeer Aziz received 10,367 shares of common stock on 10/10/2025 as equity in lieu of cash under the non‑employee director compensation policy; all shares vest immediately at a reported price of $0.
Following the transaction, Aziz directly holds 40,919 shares. The filing also lists indirect holdings of 1,995,958 shares through Adjuvant Global Health Technology Fund, L.P. and 377,542 shares through Adjuvant Global Health Technology Fund DE, L.P., with standard disclaimers that beneficial ownership is disclaimed except to the extent of pecuniary interest.